biostudies-literatureMar ACMedical Research Council and Wellcome TrustIMI-NEWMEDSMedical Research CouncilBegona Gamallo-LanaMing LeiJohan AlsioWellcome Trust2837-2857https://www.ebi.ac.uk/biostudies/studies/S-EPMC5591806biostudies-literatureUnknown234(19)<h4>Rationale</h4>Impairments in attention and inhibitory control are endophenotypic markers of neuropsychiatric disorders such as schizophrenia and represent key targets for therapeutic management. Robust preclinical models and assays sensitive to clinically relevant treatments are crucial for improving cognitive enhancement strategies.<h4>Objectives</h4>We assessed a rodent model with neural and behavioral features relevant to schizophrenia (gestational day 17 methylazoxymethanol acetate treatment (MAM-E17)) on a novel test of attention and executive function, and examined the impact of putative nootropic drugs.<h4>Methods</h4>MAM-E17 and sham control rats were trained on a novel touchscreen-based rodent continuous performance test (rCPT) designed to closely mimic the human CPT paradigm.PsychopharmacologyMAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.PMC5591806Ming Lei was supported by the Chinese Scholarshipn° 115008 of which resources are composed of EFPIG0001354The Behavioural and Clinical Neuroscience Institut350-2012-230 Johan Alsio was supported by the SwedBegona Gamallo-Lana was supported by La Caixa FellG1000183Bussey TJLei MSaksida LMMar ACGamallo-Lana BRobbins TWNilsson SROAlsio JDourado TfalseMAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.<h4>Rationale</h4>Impairments in attention and inhibitory control are endophenotypic markers of neuropsychiatric disorders such as schizophrenia and represent key targets for therapeutic management. Robust preclinical models and assays sensitive to clinically relevant treatments are crucial for improving cognitive enhancement strategies.<h4>Objectives</h4>We assessed a rodent model with neural and behavioral features relevant to schizophrenia (gestational day 17 methylazoxymethanol acetate treatment (MAM-E17)) on a novel test of attention and executive function, and examined the impact of putative nootropic drugs.<h4>Methods</h4>MAM-E17 and sham control rats were trained on a novel touchscreen-based rodent continuous performance test (rCPT) designed to closely mimic the human CPT paradigm.2017-01-01T00:00:00Z2017 Oct2026-07-15T18:32:33.529Z2019-03-27T02:55:56ZS-EPMC55918062874456310.1007/s00213-017-4679-5